Research ArticleArticle
Structural Determinants of Agonist Efficacy at the Glutamate Binding Site of N-Methyl-d-Aspartate Receptors
Kasper B. Hansen, Nami Tajima, Rune Risgaard, Riley E. Perszyk, Lars Jørgensen, Katie M. Vance, Kevin K. Ogden, Rasmus P. Clausen, Hiro Furukawa and Stephen F. Traynelis
Molecular Pharmacology July 2013, 84 (1) 114-127; DOI: https://doi.org/10.1124/mol.113.085803
Kasper B. Hansen
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (K.B.H., R.E.P., K.M.V., K.K.O., S.F.T.); Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (N.T., H.F.); and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (R.R., L.J., R.P.C.)
Nami Tajima
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (K.B.H., R.E.P., K.M.V., K.K.O., S.F.T.); Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (N.T., H.F.); and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (R.R., L.J., R.P.C.)
Rune Risgaard
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (K.B.H., R.E.P., K.M.V., K.K.O., S.F.T.); Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (N.T., H.F.); and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (R.R., L.J., R.P.C.)
Riley E. Perszyk
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (K.B.H., R.E.P., K.M.V., K.K.O., S.F.T.); Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (N.T., H.F.); and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (R.R., L.J., R.P.C.)
Lars Jørgensen
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (K.B.H., R.E.P., K.M.V., K.K.O., S.F.T.); Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (N.T., H.F.); and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (R.R., L.J., R.P.C.)
Katie M. Vance
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (K.B.H., R.E.P., K.M.V., K.K.O., S.F.T.); Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (N.T., H.F.); and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (R.R., L.J., R.P.C.)
Kevin K. Ogden
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (K.B.H., R.E.P., K.M.V., K.K.O., S.F.T.); Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (N.T., H.F.); and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (R.R., L.J., R.P.C.)
Rasmus P. Clausen
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (K.B.H., R.E.P., K.M.V., K.K.O., S.F.T.); Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (N.T., H.F.); and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (R.R., L.J., R.P.C.)
Hiro Furukawa
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (K.B.H., R.E.P., K.M.V., K.K.O., S.F.T.); Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (N.T., H.F.); and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (R.R., L.J., R.P.C.)
Stephen F. Traynelis
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (K.B.H., R.E.P., K.M.V., K.K.O., S.F.T.); Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (N.T., H.F.); and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (R.R., L.J., R.P.C.)
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Determinants of GluN2 Agonist Efficacy at NMDA Receptors
Kasper B. Hansen, Nami Tajima, Rune Risgaard, Riley E. Perszyk, Lars Jørgensen, Katie M. Vance, Kevin K. Ogden, Rasmus P. Clausen, Hiro Furukawa and Stephen F. Traynelis
Molecular Pharmacology July 1, 2013, 84 (1) 114-127; DOI: https://doi.org/10.1124/mol.113.085803
Research ArticleArticle
Determinants of GluN2 Agonist Efficacy at NMDA Receptors
Kasper B. Hansen, Nami Tajima, Rune Risgaard, Riley E. Perszyk, Lars Jørgensen, Katie M. Vance, Kevin K. Ogden, Rasmus P. Clausen, Hiro Furukawa and Stephen F. Traynelis
Molecular Pharmacology July 1, 2013, 84 (1) 114-127; DOI: https://doi.org/10.1124/mol.113.085803
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement